

Number 595 • March 2016

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by EMD Serono Canada Inc that the shortage of Serophene 50 mg Tablet (DIN 00893722) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 22, 2016.**

CLOMIPHENE CITRATE

50 MG TABLET

00000893722	SEROPHENE	SRO	\$ 5.0630
00002091879	CLOMID	SAV	\$ 5.6948

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Ipratropium 0.03% Nasal Spray (DIN 02239627) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 22, 2016.**

IPRATROPIUM BROMIDE

0.03% NASAL SPRAY

00002239627	PMS-IPRATROPIUM	PMS	\$ 0.7565
00002163705	ATROVENT	BOE	\$ 0.9930

Alberta Blue Cross has been advised by Genmed, a Division of Pfizer Canada Inc. that the shortage of GD-Quinapril 10 mg Tablet (DIN 02290995) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 25, 2016.**

QUINAPRIL

10 MG TABLET

00002248500	APO-QUINAPRIL	ΑΡΧ	\$ 0.2321
00002290995	GD-QUINAPRIL	GMD	\$ 0.2321
00001947672	ACCUPRIL	PFI	\$ 0.9238

20 MG / 12.5 MG TABLET

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Quinapril/HCTZ 20 mg/12.5 mg Tablet (DIN 02408775) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 25, 2016.**

QUINAPRIL / HYDROCHLOROTHIAZIDE

00002408775	APO-QUINAPRIL/HCTZ	ΑΡΧ	\$ 0.6865
00002237368	ACCURETIC 20/25	PFI	\$ 0.9192

Alberta Blue Cross has been advised by Ratiopharm that the shortage of Ratio-Tecnal Capsule (DIN 00608238) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 25, 2016.**

BUTALBITAL / CAFFEINE / ASA

50 MG / 40 MG / 330 MG CAPSULE

00000608238	RATIO-TECNAL	RPH	\$ 1.4687
00000226327	FIORINAL	TRI	\$ 1.5402

Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Euro Folic 5 mg Tablet (DIN 02285673) manufactured by Euro-Pharm, Jamp-Folic Acid 5 mg Tablet (DIN 02366061) manufactured by Jamp Pharma Corporation was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Euro-Pharm has advised Alberta Blue Cross that the shortage of Euro Folic 5 mg Tablet (DIN 02285673) has been resolved.

As a result, Jamp-Folic Acid 5 mg Tablet (DIN 02366061) will no longer be considered a temporary benefit for the ADBL after April 22, 2016.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.595 2016/03

